A review of cannabinoid evidence found the strongest support for neuropathic pain and MS spasticity, with average pain reduction of only 0.5-1.0 points on a 10-point scale.
pain management clinicians, patients considering cannabinoids for chronic pain, policymakers
What the researchers found
Evidence is strongest for neuropathic pain and MS-related spasticity, while results for fibromyalgia, osteoarthritis, and musculoskeletal pain remain inconsistent. Average pain reduction is modest (0.5-1.0 points on a 10-point scale). Discontinuation rates range from 4.3% at low-dose CBD to 12.9% at high-dose CBD vs. 3.5% on placebo. Nabiximols cause dizziness in 25% and somnolence in 8%.
Why it matters
Despite growing interest in cannabinoids for pain, this review provides a sobering look at the actual magnitude of benefit: modest at best, with meaningful side effects and regulatory barriers.
The numbers in context
Pain reduction: 0.5-1.0 points on a 10-point scale. CBD discontinuation: 4.3% (low dose) to 12.9% (high dose) vs. 3.5% placebo. Nabiximols: 25% dizziness, 8% somnolence, 12% treatment discontinuation. High-dose CBD carries measurable hepatotoxicity risk.
How the study worked
Narrative review of clinical outcomes, adverse effects, and legal challenges of cannabinoids in chronic pain management, synthesizing evidence from multiple conditions and formulations.
What this study cannot tell us
Narrative review without formal meta-analysis. Heterogeneous cannabinoid formulations, doses, and conditions make comparisons difficult. Regulatory differences across countries affect which data are available.
How to read the evidence
Synthesizes multiple clinical trials and reviews with specific quantitative outcomes, though narrative format without systematic methodology limits to moderate.
When this study was published
Contemporary review of current cannabinoid pain evidence.
The bigger picture
This review positions cannabinoids as adjunctive rather than first-line pain therapies, reserved for patients who do not respond to conventional treatment. The modest effect sizes and notable side effect profiles suggest cannabinoids are not the breakthrough pain solution some hope for.
Questions still open
- Would standardized cannabinoid formulations produce more consistent results?
- For which specific pain conditions do cannabinoids outperform existing treatments?
Common questions
How much pain relief do cannabinoids actually provide?
What are the main side effects?
Read the original research
Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges.
Neurology international, 17(9)
Citation
Sic, Aleksandar; George, Conor; Gonzalez, Daniela Ferrer; Tseriotis, Vasilis-Spyridon; Knezevic, Nebojsa Nick. (2025). Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges.. Neurology international, 17(9). https://doi.org/10.3390/neurolint17090141
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- Cannabis and Fibromyalgia: Evidence, Dosing, and What Patients Report
- Cannabis and Carpal Tunnel: Can THC Help Nerve Pain